The duration of targeted therapy for gastric cancer patients is as follows: 1. Targeted therapy against tumor cells: treatment with monoclonal antibodies such as Herceptin, which generally lasts for a long time. If certain efficacy is obtained, the treatment can be continued until the disease is stabilized or the opportunity of surgery arises; 2. Targeted therapy for blood vessels: generally, it is a long-term treatment. Small molecule drugs for vascular targeting therapy need to maintain blood oxygen concentration, so the duration is relatively long, and may produce relatively serious side effects, such as bleeding. The specific medication should be combined with the clinical and guided by the doctor’s face-to-face consultation.